Purpose and Summary
The ``DHS Biodetection Improvement Act,'' directs the
Secretary of the Department of Homeland Security (DHS) to
conduct an assessment of how DHS has utilized the Department of
Energy's national laboratories and sites to address homeland
security needs. This legislation directs DHS to submit a
strategy for how the Department will coordinate with the
Department of Energy's national laboratories to address
biodetection research and development.
H.R. 6174 also requires the Secretary of Homeland Security
to provide an update to the House Committee on Homeland
Security and the Senate Committee on Homeland Security and
Governmental Affairs regarding the assessment and strategy.
Background and Need for Legislation
In response to the 2001 anthrax attacks, DHS established
the BioWatch Program, which is a monitoring system that
collects and tests air samples for biological agents likely to
be used in a bioterrorism attack. Currently operated by the
Countering Weapons of Mass Destruction Office (CWMD), the
technology behind the BioWatch Program was originally developed
in coordination with the Department of Energy's national
laboratories.
Operating in over 30 major metropolitan areas across the
United States, the program is locally managed through a
cooperative funding agreement with DHS. The BioWatch system has
been routinely criticized due to the inability to inform
officials in real-time and the common occurrence of false
alarms stemming from its failure to always distinguish between
harmless germs and the lethal pathogens that terrorists would
be likely to unleash in an attack.
In 2019, DHS began a major acquisition program, Biological
Detection for the Twenty First Century (BD21), to move toward
the next generation of national biodetection. The BD21 program
is intended to address some of BioWatch's limitations,
including shortening the detect-to-warn timeline. Additionally,
this second iteration of biodetection capability seeks to
produce more accurate and reliable results. However, DHS has
faced continuous challenges in acquiring biodetection
capabilities to replace BioWatch, as highlighted in a May 2021
report from the Government Accountability Office (GAO) (GAO-21-
292).
While DHS has the authority to utilize the Department of
Energy's national labs to identify and develop new technologies
related to biodefense, to date, DHS has underutilized that
resource. H.R. 6174 will work to address this issue of
underutilization by requiring DHS to submit a strategy for how
the Department will coordinate with the Department of Energy's
national laboratories to address biodetection research and
development. Furthermore, this bill will help DHS establish a
blueprint for what the future of biodefense should look like.
Hearings
For the purposes of clause 3(c)(6) of rule XIII of the
Rules of the House of Representatives, the Committee did not
hold a legislative hearing on H.R. 6174 in the 118th Congress;
however, during the 116th and the 117th Congresses, the
following hearings informed H.R. 6174:
On October 17, 2019, the Emergency Preparedness, Response,
and Recovery Subcommittee of the Committee on Homeland Security
held a hearing entitled, ``Defending the Homeland from
Bioterrorism: Are We Prepared?'' and received testimony from
Ms. Asha M. George, DrPH, Executive Director, Bipartisan
Commission on Biodefense; Ms. Jennifer Rakeman, PhD, Assistant
Commissioner and Director, Public Health Laboratory, Department
of Health and Mental Hygiene, New York, NY; and Mr. Umair A.
Shah, MD, MPH, Executive Director, Public Health, Harris
County, TX.
On July 16, 2021, the Emergency Preparedness, Response, and
Recovery Subcommittee of the Committee on Homeland Security
held a hearing entitled, ``Examining the U.S. Department of
Homeland Security Countering Weapons of Mass Destruction
Office,'' and received testimony from the Honorable Gary
Rasicot, Acting Assistant Secretary, CWMD, DHS; and Mr.
Christopher P. Currie, Director, Homeland Security and Justice,
GAO.
Committee Consideration
The Committee met on Wednesday, November 8, 2023, a quorum
being present, to consider H.R. 6174 and ordered the measure to
be favorably reported to the House by voice vote.
Committee Votes
Clause 3(b) of rule XIII requires the Committee to list the
recorded votes on the motion to report legislation and
amendments thereto.
No recorded votes were requested during consideration of
H.R. 6174.
Committee Oversight Findings
In compliance with clause 3(c)(1) of rule XIII, the
Committee advises that the findings and recommendations of the
Committee, based on oversight activities under clause 2(b)(1)
of rule X, are incorporated in the descriptive portions of this
report.
Congressional Budget Office Estimate, New Budget Authority, Entitlement
Authority, and Tax Expenditures
With respect to the requirements of clause 3(c) of rule
XIII and section 308(a) of the Congressional Budget Act of
1974, and with respect to the requirements of clause 3(c)(3) of
rule XIII and section 402 of the Congressional Budget Act of
1974, the Committee adopts as its own the estimate of any new
budget authority, spending authority, credit authority, or an
increase or decrease in revenues or tax expenditures contained
in the cost estimate prepared by the Director of the
Congressional Budget Office.
H.R. 6174 would require the Department of Homeland Security
(DHS), within 180 days of enactment, to report to the Congress
on its use of the Department of Energy's national laboratories
and on a strategy to improve biodetection capabilities at DHS.
The department's efforts to prevent the use of biological and
chemical weapons include testing and monitoring air quality for
potential biological threats, conducting research, and
promoting readiness against such attacks by partnering with
state, local, and tribal governments. H.R. 6174 also would
require DHS to provide an update on the strategy to the
Congress within one year of enactment.
Based on the cost of similar activities, CBO estimates it
would cost DHS less than $500,000 in administrative and
personnel costs over the 2024-2028 period to compile and
implement the strategy. Any spending would be subject to the
availability of appropriated funds.
The CBO staff contact for this estimate is Jeremy Crimm.
The estimate was reviewed by H. Samuel Papenfuss, Deputy
Director of Budget Analysis.
Phillip L. Swagel,
Director, Congressional Budget Office.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act of 1995.
Duplicative Federal Programs
Pursuant to clause 3(c) of rule XIII, the Committee finds
that H.R. 6174 does not contain any provision that establishes
or reauthorizes a program known to be duplicative of another
Federal program.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the objective of
H.R. 6174 is to improve the Department of Homeland Security's
utilization of the Department of Energy's national laboratories
and sites to identify and develop new technologies related to
biodefense.
Congressional Earmarks, Limited Tax Benefits, and Limited Tariff
Benefits
In compliance with rule XXI, this bill, as reported,
contains no congressional earmarks, limited tax benefits, or
limited tariff benefits as defined in clause 9(d), 9(e), or
9(f) of rule XXI.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act (5 U.S.C. Sec. 1004) were
created by this legislation.
Applicability to the Legislative Branch
The Committee finds that H.R. 6174 does not relate to the
terms and conditions of employment or access to public services
or accommodations within the meaning of section 102(b)(3) of
the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
This section states that the Act may be cited as the ``DHS
Biodetection Improvement Act.''
Sec. 2. DHS utilization of department of energy national laboratories
and sites for certain biodetection research and development
relating to the missions of the DHS.
This section directs the Secretary of Homeland Security to
conduct an assessment of how DHS has utilized the Department of
Energy's national laboratories and sites regarding research and
development in carrying out the missions of the Department.
This section requires DHS to submit the assessment to the House
Committee on Homeland Security and the Senate Committee on
Homeland Security and Governmental Affairs no later than 180
days after the date of enactment.
This section also directs DHS to submit a strategy for how
the Department will coordinate with the Department of Energy's
national laboratories to address biodetection research and
development. The strategy must include the following:
Identify and then develop an acquisition and
procurement plan to acquire the identified biodetection
technologies that can, either individually or together,
meet the Department's biodetection mission needs.
Conduct periodic external evaluations to
identify gaps and potential failure points with respect
to such biodetection technologies and recommend
contingency plans for underperforming technologies.
Develop clearly defined program and
technical requirements for future DHS biodetection
programs.
Lastly, this section requires that no later than one year
after the date of enactment, the Secretary of Homeland Security
must provide an update to the House Committee on Homeland
Security and the Senate Committee on Homeland Security and
Governmental Affairs regarding the assessment and strategy,
including any challenges to implementing the strategy.
[all]